Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label study of KCMC-001 vaccine in multidrug-resistant pulmonary tuberculosis
jRCT2053190023Phase 1Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Nov 2019
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KCMC-001 in pulmonary tuberculosis (TB), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Safety and tolerability of KCMC-001, Systemic exposure to plasmid DNA and 3 more. Started Nov 2019; status: completed.
02
Drugs
KCMC-001
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on jRCT2053190023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2053190023.